Significantly, we demonstrated that ILT4 inhibition reversed the immunosuppressive TME and might be a promising strategy for the second-line treatment of TKI-resistant EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.